Acute myeloid leukemia (AML) patients treated with available therapies achieve remission in approximately 60% of cases, but the long-term event-free survival is less than 30%. Use of immunotherapy during remission is a potential approach to increase survival. We propose to develop cell vaccines by genetic modification of AML cells with CD80, an essential T cell costimulator that is lacking in the majority of AML cases, and GM-CSF, to induce proliferation and activation of professional antigenpresenting cells. Here, we evaluated third generation selfinactivating ( 
Introduction
Acute myeloid leukemia is the most frequent type of leukemia in adults. Conventional therapies produce hematological remissions in 50-60% of patients, but only 25-30% of adult patients with AML survive for longer than 3 years. 1 Efforts to optimize current treatment modalities, including chemotherapy and stem cell transplantation (SCT), have so far failed to significantly improve overall median survival. 2 Further, effective therapy of older patients is compromised by the relative toxicity of intensive chemotherapy. Thus, novel adjuvant treatment approaches are clearly needed.
It is now well established that the immune system plays an important role in inducing anti-leukemia responses. In the allogeneic SCT setting for chronic myelogenous leukemia (CML), it has been convincingly demonstrated that donor lymphocytes may promote immune rejection of leukemia, with resultant long-term survival of the recipient. 3 It is clear, however, that the graft-versus-leukemia effect after allogeneic SCT is weaker for acute myeloid leukemia than for CML. 4 The reasons for the escape of acute leukemia cells from immune surveillance are not fully understood, but it is possible that intrinsic or acquired properties of leukemia cells per se help them to evade or inhibit immune recognition. Active immunization against leukemia given at the time of complete remission when tumor burden is reduced, is a potential strategy to overcome immunological unresponsiveness, with elimination of minimal residual disease. [5] [6] [7] AML is a heterogeneous disease and AML-specific or associated anti- gens have not yet been clinically demonstrated. Therefore, a whole cell vaccine approach could provide tools to generate anti-leukemia immunity in the autologous and allogeneic settings and to further characterize antigenic determinants in AML cells.
AML cells per se are poor antigen-presenting cells (APC). For most patients, AML cells express both MHC class I and class II molecules required for antigen presentation. 8, 9 However, they lack the expression of co-stimulatory ligands or inflammatory cytokines to promote strong immune responses. In fact, expression of the co-stimulatory ligand CD80 has been reported to occur in less than 10% of analyzed AML samples. 9 We and others have adopted strategies to overcome the poor APC status of AML blasts by direct gene transfer of immunomodulators and/or hematopoietic regulators into AML cells. 6, 7, 10 Several transplantable murine AML models have demonstrated the feasibility of anti-leukemia immunization using genetically modified leukemia cells expressing CD80 and/or granulocyte-macrophage colony-stimulating factor (GM-CSF). [11] [12] [13] [14] [15] [16] As AML cell vaccines move towards clinical application, efficient and safe genetic vectors to transduce primary human leukemia cells will be required. We recently developed and characterized the use of HIV-derived lentiviral vectors for delivery and expression of CD80 and GM-CSF into human leukemia cell lines and primary cells. Thus, VSV-G pseudotyped, second generation lentiviral vectors promoted consistent, efficient and stable expression of CD80 and GM-CSF in primary AML and acute lymphocytic leukemia cells (ALL). 10 To minimize the potential risk of replication-competent lentivirus with HIV-derived lentiviral vectors, third generation self-inactivating (SIN) vectors have been devised for future clinical applications. 17, 18 In this report, we evaluated the efficiency of AML blast transduction with third generation SIN lentiviral vectors expressing GM-CSF, CD80 and GM-CSF plus CD80. The biological activity of endogenous GM-CSF production by AML cells was assessed by proliferation and viability assays, morphology and immunophenotype. The immunological effects of GM-CSF and/or CD80 expression by AML cells on T cell stimulation was evaluated in the allogeneic and autologous settings. The data demonstrate the feasibility of using the novel vectors for immunomodulatory gene transfer into AML cells and, importantly, the ability of these gene-modified cells to enhance T cell immune responses.
Materials and methods

Cell lines
The 293T cell line was obtained from ATCC (Rockville, MD, USA), and the 293A line is a more adhesive subclone of 293 cells (Q-Biogene, Carlsbad, CA, USA). The human leukemia cell lines used in this study were Nalm-6 (kindly provided by Dr Dario Campana, St Jude Children's Research Hospital, Memphis, TN, USA), AML-5 (kindly provided by Dr Dario Campana) and TF-1 (obtained from R&D Systems, Minneapolis, MN, USA).
Cell Culture
293T cells were cultured in Dulbecco's modified Eagle's medium with L-glutamine (DMEM; BioWittaker, Walkersville, MD, USA), 10% fetal bovine serum (FBS) and penicillin/streptomycin (50 U/ml). The leukemia cell lines were cultured in RPMI 1640 medium with L-glutamine (BioWittaker), 10% FBS and penicillin/streptomycin (50 U/ml). For the cell line AML-5, human interleukin-6 (IL-6; R&D Systems) was added to the medium to a final concentration of 10 ng/ml. Cells were incubated at 37ºC and 5% CO 2 . Experiments were performed with cells in exponential growth phase and all transductions were performed in AIM-V serumfree medium (GIBCO/BRL, Grand Island, NY, USA).
Primary cells
Primary cells were obtained from peripheral blood samples and bone marrow aspirates from adult AML patients at diagnosis and remission. The samples were obtained and studies performed in accordance with protocols approved by the Institutional Review Board of the University of Southern California, after informed consent. Mononuclear cells were separated by density gradient centrifugation, cryopreserved in 10% dimethyl sulfoxide (DMSO) and 90% FBS and stored in the Tissue Procurement Cell Bank of the University of Southern California. These cells were thawed at 37°C for 1 h using a thawing medium containing AIM-V, 30% FBS, 20 U/ml heparin and 0.2 U/ml DNAse (Roche, Indianapolis, IN, USA). After thawing, primary cells were washed twice with AIM-V medium. Primary AML cells were cultured in AIM-V medium containing 10 ng/ml human interleukin-3 (IL-3) and 50 ng/ml human stem cell factor (SCF; R&D Systems).
T cell purification
Mononuclear cell suspensions prepared from peripheral blood were incubated with a cocktail of monoclonal antibodies and a magnetic colloid to enrich human T cells (StemCell Technologies, Vancouver, BC, Canada). T cells were obtained as the flow-through after running the pre-bound cells through a LS magnetic separation column (Miltenyi Biotec, Auburn, CA, USA).
Construction of RRL-CD80, RRL-GM-CSF and RRL-GM/CD vectors
The backbone vector used for insertion of the immunomodulatory genes consisted of a derivative of the pRRL-sin.hCMV-GFP-pre construct, 17 where the GFP cDNA was deleted by XbaI/SalI deletion and replaced by a polylinker containing a multiple cloning sites (MCS; CTAGAACTAGTGGATCCC CCGGGCTGCAGGAATTCGATATCAAGCTTATCGATACCG), resulting in the vector pRRL-sin.hCMV-MCS-pre. The EcoRI site present in the backbone of the original pRRL-sin.hCMV-GFP-pre construct was eliminated by a point mutation introduced by PCR resulting into the backbone vector pRRLsin.hCMV-MCS-pre ∆Eco. DNA fragments obtained by EcoRI digestion of pHR-CD80, pHR-GM-CSF, and a partial digestion of the bi-cistronic pHR-GM/CD plasmids 10 and encoding the respective immunomodulatory genes were introduced into the EcoRI site present in the multiple cloning site of the vector pRRL-sin.hCMV-MCS.∆Eco to generate RRL-CD80, RRL-GM-CSF and RRL-GM/CD. All constructs were reconfirmed by restriction digestion and sequencing analysis.
Production of lentivirus
The constructs required for the packaging of second or third generation self-inactivating lentiviral vectors were previously described. [18] [19] [20] The construct pMD.G was used for the production of the VSV-G viral envelope in combination with the packaging construct pCMV∆8.9 (second generation) or pMDLg/pRRE plus RSV-REV (third generation). Lentivirus vectors were produced by transient co-transfection of 293T cells with the backbone vector plasmid derived from the pHR-or RRL series, plus the packaging plasmids and pMD.G as previously described. 10, 18, 20 Viral titer was determined by assessing viral p24 antigen concentration by ELISA (Coulter Immunotech, Miami, FL, USA). The minimum detectable p24 concentration for this assay is 3 pg/ml.
Lentiviral-mediated gene transfer
Leukemia cells were washed twice with AIM-V and for each transduction point 1-2 × 10 6 cells were mixed with AIM-V and lentiviral vectors at the final concentration of 5 g/ml of p24 equivalent. One milliliter of the cell/viral suspension was seeded per well of six-well plates, protamine sulfate was added at the final concentration of 6 g/ml and the transduction plates were incubated at 37°C, 5% CO 2 overnight. Leukemia cells were washed twice with AIM-V medium, and seeded at a density of 10 6 cells/ml in AIM-V and cytokines. Twentyfour hours later, the supernatant was collected for ELISA and the cells were harvested for FACS analysis or kept in culture for analyses at further time points.
FACS analysis
For analysis of GFP expression, cells were washed once with phosphate-buffered saline (PBS) and resuspended in 100 l of 1% paraformaldehyde for fixation. For analysis of surface membrane antigens, cells were washed once with phosphatebuffered saline, incubated with PBS containing mouse IgG (50 g/ml) for 15 min on ice, stained with the corresponding monoclonal antibody for 20 min, washed and resuspended in 100 l of 1% paraformaldehyde for fixation. The monoclonal antibodies to CD80 and CD86 and respective isotype monoclonal antibodies were conjugated with FITC and the monoclonal antibodies against CD33 and CD1a respective isotype monoclonal antibodies were conjugated with phycoerthrin (Pharmingen, La Jolla, CA, USA). Flow cytometric analysis was accomplished with a FACScalibur cytometer equipped with a 488-nm argon laser. To establish background for fluorescence and to set gates for data acquisition, staining with isotype antibodies was used. Care was taken to analyze cells present in the myeloblast gate based on forward and side scatter characteristics.
Analysis of GM-CSF
Expression of GM-CSF was analyzed by ELISA (R&D Systems) according to the manufacturer's instructions. The minimum detectable concentration of GM-CSF following this assay is typically less than 3 pg/ml. 
Analysis of proliferation and viability
Mixed lymphocyte reactions (MLR)
Irradiated (3200 cGy) primary non-transduced or transduced AML cells were used as stimulators. AML cells were co-cultured at a 1:2 ratio with allogeneic T cells or autologous PBMC, in 96-well round-bottom plates containing 10 5 AML and 2 × 10 5 responder cells in 200 l of medium and incubated for 6 days at 37°C in a 5% CO 2 incubator. All MLR cultures were carried-out in RPMI-1640 supplemented with 5% heat-inactivated human AB serum (Omega, Tulare, CA, USA). For autologous MLR, 10 U/ml recombinant human interleukin-2 (IL-2; R&D Systems) was added for the last 3 days of culture. All microcultures were performed in triplicate. Cells were pulsed with 1 Ci of 3 H-thymidine (Du Pont) for the last 18 h of the culture period, and then harvested on to glass fiber filters. 
Analysis of activated T cells by flow cytometry
Results and discussion
Third generation SIN lentiviral vectors efficiently transduce AML cells
Third generation SIN vectors are currently being considered for clinical testing in humans. Therefore, this gene transfer system was evaluated for potential use as an AML cell vaccine, genetically modified to express GM-CSF and/or CD80. The SIN transfer vector construct contains HIV cis-acting sequences and an expression cassette for the transgenes. The transgene is the only portion transferred to target cells, and upon integration, does not carry wild-type copies of the HIV LTR to the host DNA. The 5′ LTR is chimeric, with the enhancer/promoter of RSV replacing the U3 region of the HIV LTR to rescue its transcriptional dependence on tat. The 3′ LTR has an almost complete deletion of the U3 region, which includes the TATA box. As the latter also serves as the template to regenerate the U3 region in the 5′ LTR, upon reverse transcription, transcriptional inactivation of both LTRs in the integrated provirus occurs. 17 The RRL-sin backbone used in our studies also contains the hCMV internal promoter and a post-transcriptional regulatory element ('pre') from the woodchuck hepatitis virus in the 3′ untranslated region of the transgenes, to increase RNA stability and therefore protein production. 20 Batches of SIN third generation lentiviral vectors were produced by transient co-transfection of 293T cells and were concentrated by ultracentrifugation. The virus titer was quantified by measuring the concentration of gag p24, a protein present in the core of the lentiviral vectors. We determined experimentally in titration assays using 293T cells that 1 g of p24 is roughly equivalent to 10 7 infection units (data not shown). The p24 concentration was found to be consistent between viral batches, with an average of 20 g/ml, which would be equivalent to titers of 2 × 10 8 infective particles/ml. We determined by transduction experiments of the Nalm-6 and AML-5 cell lines that 2-10 g/ml of p24 equivalent of the RRL-sin.hCMV.GFP.pre vector consistently produced Ͼ90% transduction of 2 × 10 6 cells (data not shown). Therefore, for all experiments we used 5 g of p24 equivalent of each lentiviral vector in the transduction of 2 × 10 6 cells in 1 ml of culture. At this concentration, where the multiplicity of infection (MOI) is approximately 25, we did not observe cellular toxicity after transduction.
We initially tested the feasibility of primary AML cell transduction with the reporter RRL-sin.hCMV.GFP.pre lentiviral vector. Initial diagnostic samples of bone marrow and peripheral blood were obtained from adult patients, after approval of the USC Institutional Review Board, and obtaining written informed consent. The samples used contained 80% or higher of leukemia blasts as determined by immunophenotype and morphology. The phenotypic features of the leukemia samples used in this study are shown in Table 1 . Cryopreserved samples were thawed and maintained in AIM-V medium plus hIL-3 and hSCF overnight, before transduction. After exposure to RRL-sin.hCMV.GFP.pre overnight, leukemia cells were Table 1 ). Transduction of blood or bone marrow leukemia specimens from the same patient resulted in similar percentages of GFP + cells and of GFP expression levels ( Figure 1 ).
SIN vectors encoding CD80 and GM-CSF show improved expression in cell lines
We then compared the self-inactivating RRL-GM/CD bicistronic vector co-expressing CD80 and GM-CSF with the pHR-GM/CD vector that we previously used in transduction assays. The pHR-vector series retain the wt HIV LTRs, which can result in transcriptional interference with the internal hCMV promoter. In fact, the pHR-GM/CD vector was previously shown to produce detectable CD80 expression, but poor expression of the upstream GM-CSF gene, which was suggested to be due to low levels and/or instability of the mRNA transcribed from the hCMV promoter. 10 The novel RRL-vector series has two features designed to improve transgenic expression. First, due to its self-inactivating function, hCMV is the only functional promoter after viral integration, and therefore, promoter interference should no longer play an inhibitory role in the mRNA expression. Second, the presence of the pre element in the 3′ untranslated region should provide stabilization of the transcript and therefore higher mRNA levels.
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Figure 1
Primary AML cells obtained from blood or bone marrow were transduced with the RRL-sin.hCMV.GFP.pre vector packaged in the vesicular stomatitis virus G envelope. Forty-eight hours after transduction, GFP expression was followed by flow cytometry. The percentage of GFP + cells was calculated by subtracting the frequency of the transduced cells (bold lines) from the background, mock controls (broken lines).
To achieve comparable conditions during the packaging process to produce RRL-and pHR-vectors, viral supernatants were produced in triplicate by transient co-transfection with the second-generation pCMV.∆8.9 packaging plasmid, the pMD.G envelope expression vector and equal molar amounts of the RRL-GM/CD or pHR-GM/CD transfer vectors. Comparable levels of p24 were measured among the different viral preparations (2 g/ml), indicating that the level of virion production was consistent between the two vector preparations. One milliliter was used to transduce 293A fibroblasts and the Nalm-6 acute leukemia cell line. Under these transduction conditions we expected to yield one transduction event per Nalm-6 cell according to titration experiments using GFP as reporter. Forty-eight hours after transduction, CD80 and GM-CSF expression were measured by flow cytometry and ELISA, respectively. Both vectors produced Ͼ90% transduction, as measured by the percentage of CD80 + cells by flow cytometry (data not shown). Therefore, the two vector types did not differ significantly in their transduction efficiencies.
The CD80 expression level (measured as mean fluorescence units, MFU, by FACS) was 50% higher in 293A and Nalm-6 cells transduced with the RRL-GM/CD vector ( Figure 2) . A significant increase in GM-CSF production was observed for 293A (Ͼ9-fold) and Nalm-6 (Ͼ3-fold) cells transduced with the SIN vector ( Figure 2 ). Relative increases in the transgene expression levels were also observed after transduction of 293A cells with the monocistronic vectors encoding CD80 (MFU for CD80 was 136 and 181 for pHR-and RRL-backbones, respectively) and GM-CSF (GM-CSF production was 57 and 399 ng/ml for pHR-and RRL-backbones, respectively) (data not shown). Therefore, the safer SIN vectors surpassed the second generation lentiviral vectors in terms of CD80 and GM-CSF expression levels. 
Leukemia
Efficient expression of CD80 and GM-CSF in primary leukemia cells
The transduction of primary AML blasts with the third generation SIN vectors was evaluated in two distinct primary leukemia samples transduced with either RRL-GMCSF alone, with RRL-CD80 alone, with a combination of RRL-CD80 plus RRL-GMCSF, or with the bicistronic vector RRL-GM/CD. Transduction efficiency assessed by percentage of CD80 + cells was slightly higher for RRL-CD80 alone or in combination with RRL-GM-CSF than for RRL-GM/CD. CD80 and GM-CSF expression were, respectively, Ͼ2-fold and Ͼ10-fold higher for the monocistronic vectors than for the bicistronic RRL-GM/CD vector (Figure 3 ). These results demonstrate that efficient CD80 and GM-CSF co-expression could be achieved in primary leukemia cells either by co-transduction with two monocistronic SIN vectors or by transduction with the bicistronic SIN vector alone.
Transduction of primary AML cells is stable and continuous expression of GM-CSF leads to phenotypic changes in the cell population
The long-term effects of CD80 and GM-CSF expression in transduced primary AML cells were characterized in cultures with prolonged viability, without addition of exogenous cytokines. In Figure 4 we show the results from primary leukemia cells that could be maintained in culture for 17 days after the transduction with RRL-GM-CSF, RRL-CD80, RRL-GMCSF plus RRL-CD80 or with RRL-GM/CD. As assessed by flow cytometry analysis of the non-transduced sample (mock), most of the cells marked in the myeloblast region (R1) expressed the myeloid CD33 marker, consistent with the AML phenotype. Persistent expression of CD80 by cells within the myeloblast population was observed for AML/RRL-CD80, but not for AML/RRL-GM/CD cells, suggesting that overall expression from the latter vector was unstable and/or CD80 expression was specifically down-regulated during prolonged culture. Cells transduced with RRL-GMCSF or RRL-GM/CD vectors showed a profound change in phenotype, as observed by a population of larger cells (R2), which expressed the CD33 antigen and CD80. This population of large cells (even larger than the population within the myeloblast gate, (R1)) also expressed low levels of CD86 and CD1a, which are surface antigens typically expressed by dendritic cells. For these analyses, matched isotype control antibodies were used to set up the positive and negative quadrants (data not shown). Therefore, GM-CSF production produced autocrine or paracrine effects on the cultured cells, promoting their differentiation into more mature antigen presenting cells. These results were confirmed by microscopic observation of the cells ( Figure 5 ). Non-transduced or RRL-CD80 transduced cells remained small and round, whereas RRL-GM-CSF or RRL-CD80 plus RRL-GM-CSF transduced cells were conspicuously larger, with the presence of protusions typical for dendritic cell morphology ( Figure 5 ). This induced maturation after transduction with lentiviral vectors expressing GM-CSF was observed in 3/8 primary samples studied (Table 1) .
These results may be explained by the biological activities of GM-CSF, as it is known to enhance a wide range of functions in hematopoietic precursor cells and in more mature cells of the myelomonocytic lineage. Culture of AML cells with recombinant GM-CSF, IL-3 and IL-6 has been associated with cell expansion, and with some degree of differentiation and variable up-regulation of CD80. 21 In particular, since GM-CSF and interleukin-4 (IL-4) are key in obtaining monocytederived DC cultures in vitro, 22 the strategy to drive AML cells into DC differentiation ('AML-DC') in the presence of recombinant GM-CSF and IL-4 has been studied with variable but overall successful results. [23] [24] [25] [26] It has been shown previously that autocrine stimulation after retroviral vector gene transfer of GM-CSF into multipotent murine stem cell lines (FDCP mix) induced their synchronous maturation, driving differentiation into granulocytes and macrophages. 27 To our knowledge, however, this is the first demonstration of a maturation effect in primary human AML cells after GM-CSF gene transfer. This strategy can be explored as an additional tool to optimize AML-DC production for immunotherapy.
Expression of GM-CSF stimulates proliferation and increases the metabolic rate of AML cells
In order to further characterize the biological effects of endogenous GM-CSF expression by AML cells, cell proliferation and viability assays were performed. Five different primary AML samples were transduced with RRL-GFP (to assess transduction efficiency and to serve as a base-line control for transduction effects) or with RRL-GM-CSF vectors. A factordependent human erythroleukemic cell line, TF-1, 28 commonly used in bioassays to determine the GM-CSF bioactivity, was used in parallel. The percentage of RRL-GFP transduced cells followed by GFP expression 2 days after transduction, ranged from 24 to 65% (Table 2) . GM-CSF expression in RRL-GM-CSF-transduced TF-1 cells reached Ͼ8000 ng/ml per 10 6 cells/ml in 24 h whereas primary AML cells produced in average 200 ng/ml (Table 2) . After transduction, the leukemia cells were extensively washed and seeded in microtiter plates in the absence of recombinant cytokines. The proliferation and viability were measured in parallel by 3 H-thymidine incorporation or by MTS assays on day 4 after transduction. The control TF-1 cell line showed approximately 200-fold increase in the proliferation and viability indexes. In all primary samples studied, expression of GM-CSF stimulated both proliferation and viability, with 2-to 20-fold increase in the proliferation and viability indexes ( Table 2 ). The stimulation did not correlate with the transduction efficiencies or with the levels of GM-CSF expression, indicating that intrinsic properties of the leukemia cells may account for this biological effect.
Increased allo-stimulatory activity of AML cells expressing CD80 and/or GM-CSF
We performed functional experiments to evaluate the allogeneic T cell response to transduced AML cells. We compared the T cell stimulatory activity of AML primary cells that were either non-transduced (mock), transduced to express the control transgene GFP (AML/RRL-GFP), or transduced to express GM-CSF (AML/RRL-GM-CSF), CD80 (AML/RRL-CD80) or a combination of both (AML/RRL-GM/CD). Two days after transduction, expression of GM-CSF and of CD80 were confirmed by ELISA and FACS, respectively (Figure 6a ). The transduced AML cells were irradiated (3200 cGy) and co-incubated with purified T cells in a mixed lymphocyte culture (MLR). As a control for T cell stimulation, PHA was added to a subset of T cells. Six days later, the cultures were labeled with 3 H-thymidine for 16 h and harvested. The incorporated radioactivity was measured, and PHA-treated T cells showed Ͼ40 000
Figure 4
Immunophenotypic analysis of transduced primary AML cells maintained in culture for 17 days in the absence of recombinant cytokines. Upper panels: flow cytometric forward vs side scatter dot-plot showing R1 (leukoblast gate) and R2 (matured cells gate). Middle panels: dot-plot analysis of the double staining for the CD33 myeloid lineage marker (phosphatidyllethanolamine-conjugated anti-CD33) and transgene/endogenous co-stimulatory molecule expression (fluorescein isothiocyanate-conjugated anti-CD80). Lower panels: dot-plot analysis of the double staining for the CD1a dendritic cell marker (phosphatidyllethanolamine-conjugated anti-CD1a) and co-stimulatory molecule CD86 expression (fluorescein isothiocyanate-conjugated anti-CD86). Isotype non-specific control antibodies were used to set up the background levels.
c.p.m., in contrast to non-treated T cells (Ͻ100 c.p.m., data not shown). Allo-reactivity, measured as SI, was observed for all co-cultures (Figure 6a ). AML/RRL-GM-CSF, AML/RRL-CD80 and AML/RRL-GM/CD stimulated T cells significantly (P = 0.05) when compared to AML/Mock, whereas non-significant values were obtained for the co-culture with AML/RRL-GFP (Figure 6a ). In parallel, T cells that were kept for 6 days in MLR were also characterized for the percentage of CD4
+ and CD8 + activated subpopulations. As shown in Figure 6b , the percentage of CD4 + cells within the CD3 + gate remained uniform for all co-cultures, whereas the numbers of CD8
+ cells increased when T cells were co-incubated with AML cells expressing GM-CSF. This was correlated with Leukemia higher numbers of cells expressing CD69, a marker for lymphocyte activation (Figure 6b ). Activation of CD4
+ cells was also enhanced by co-culture with AML/RRL-GM-CSF cells. Interestingly, we did not observe a noticeable increase of CD69 + cells in the co-cultures containing AML/RRL-CD80 cells, despite the fact that they provided the highest T cell proliferation. One possible reason is that the stimulation provided by AML cells expressing GM-CSF may have a more persistent profile, due to the combined professional APC functions (co-stimulated expression of MHC and co-stimulatory molecules). 
Increased auto-stimulatory activity of AML cells expressing CD80 and/or GM-CSF
In another set of experiments, we performed co-cultures of primary AML cells as stimulators and autologous bone marrow mononuclear cells as responders, essentially as described previously for the allogeneic system. Expression of GM-CSF and CD80 two days after transduction was detected in the transduced cells (Figure 7a ). Co-culture of mononuclear cells with non-transduced AML cells produced only low levels of stimulation (Ͻ100 c.p.m.), whereas the PHA stimulated controls showed Ͼ12 000 c.p.m. (data not shown). Co-culture with AML/RRL-GFP, AML/RRL-GM-CSF and AML/RRL-CD80 showed modest SI values, surpassed only by AML/RRL-GM/CD (the increase is not significant at P = 0.05). This experiment was repeated, and similar findings obtained, showing that AML/RRL-GM/CD and AML/RRL-GM-CSF were the best inducers of proliferation (data not shown). Since the proliferation of autologous reactive T cells can be increased by various rounds of T cells stimulation, 10 this approach can be used in the future to obtain anti-AML-specific T cell clones. Table 2 Transduction of primary leukemia cells to express GFP or GM-CSF followed by proliferation and viability assays To demonstrate that the effect on the proliferation of PBMC was correlated with T cell activation, flow cytometry analysis of CD4 + and CD8 + cells was performed. T helper responses. This result has favorable implications for immunotherapy, as CD4 + cells appear to sustain long-lasting immunity, in contrast with the short duration of immunity elicited by CD8
+ cells. The effects of transduced AML cells on CD4 + and CD8 + autologous stimulation will be next examined in further detail by in vitro assays, in order to characterize the antigenic determinants. Importantly, the effects of irradiation on the expression of CD80 and GM-CSF by transduced cells, and the concomitant immune effects also demand examination.
Thus, in agreement with other groups, we found that upregulation of CD80 expression on AML cells by gene transfer 29 and exposure of AML to GM-CSF 23, 24 can both lead to T cell stimulatory responses, which can be combined by lentiviral gene transfer of both genes.
The demonstration by Dranoff and colleagues of anti-tumor responses produced by tumor cell vaccines expressing GM-CSF in mouse and man has been a strong motivation for the field. 30, 31 The mechanism proposed for this effect was the microenvironment produced by GM-CSF secretion, causing a potent paracrine stimulation of professional APCs in the vaccination site. For primary human AML cells, we were able to show that the GM-CSF expression produced autocrine/paracrine effects in the leukemia cells per se, directing them towards the APC phenotype. The finding that GM-CSF expression by transduced AML cells can trigger their differentiation into AML-APC after extended culture has important implications for immunotherapy purposes, and remains to be further characterized before considering its Leukemia clinical application. The initial vaccination procedure will therefore involve administration of irradiated leukemia cells 48 h after transduction, as simulated by the functional assays presented here.
In conclusion, the cumulative data obtained from various acute leukemia murine models strongly support the strategy of CD80 and/or GM-CSF gene transfer to generate acute leukemia cell vaccines. 11, 12, 15, 16, [32] [33] [34] Our current results have demonstrated the feasibility of translating this approach to a clinical setting utilizing potentially safer third generation SIN lentiviral vectors.
